WASHINGTON, Jan 31 (Reuters) - Biotechnology company SGX Pharmaceuticals Inc. on Tuesday cut the price of its pending initial public offering to $6 to $7 per share, from $7 to $8.
WASHINGTON, Jan 31 (Reuters) - Biotechnology company SGX Pharmaceuticals Inc. on Tuesday cut the price of its pending initial public offering to $6 to $7 per share, from $7 to $8.